Table 4.
Predictive Value of the SII Level and Different Glycemic Metabolism Status for Primary and Secondary Endpoints
| Variables | Events/Subjects | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI)*,† | P value | ||
| MACE | |||||
| SII-H/T2DM | 129/1440 | Reference | NA | Reference | NA |
| SII-L/T2DM | 166/2516 | 0.72 (0.57–0.91) | 0.005 | 0.77 (0.61–0.98) | 0.036 |
| SII-H/Non-T2DM | 92/1687 | 0.60 (0.46–0.78) | <0.001 | 0.66 (0.50–0.87) | 0.003 |
| SII-L/Non-T2DM | 135/2959 | 0.50 (0.39–0.63) | <0.001 | 0.58 (0.45–0.74) | <0.001 |
| MI+All-cause mortality | |||||
| SII-H/T2DM | 41/1440 | Reference | NA | Reference | NA |
| SII-L/T2DM | 51/2516 | 0.71 (0.47–1.07) | 0.097 | 0.84 (0.54–1.29) | 0.421 |
| SII-H/Non-T2DM | 36/1687 | 0.75 (0.48–1.17) | 0.206 | 0.97 (0.61–1.56) | 0.906 |
| SII-L/Non-T2DM | 39/2959 | 0.46 (0.30–0.71) | <0.001 | 0.61 (0.38–0.98) | 0.042 |
| All-cause mortality | |||||
| SII-H/T2DM | 29/1440 | Reference | NA | Reference | NA |
| SII-L/T2DM | 26/2516 | 0.51 (0.30–0.86) | 0.012 | 0.66 (0.38–1.17) | 0.158 |
| SII-H/Non-T2DM | 22/1687 | 0.65 (0.37–1.13) | 0.123 | 0.86 (0.48–1.54) | 0.602 |
| SII-L/Non-T2DM | 25/2959 | 0.42 (0.24–0.71) | 0.001 | 0.64 (0.36–1.14) | 0.127 |
| MI | |||||
| SII-H/T2DM | 357/1440 | Reference | NA | Reference | NA |
| SII-L/T2DM | 282/2516 | 0.46 (0.39–0.54) | <0.001 | 0.65 (0.55–0.76) | <0.001 |
| SII-H/Non-T2DM | 376/1687 | 0.95 (0.82–1.09) | 0.46 | 0.98 (0.84–1.14) | 0.775 |
| SII-L/Non-T2DM | 344/2959 | 0.47 (0.41–0.55) | <0.001 | 0.64 (0.54–0.75) | <0.001 |
| TVR | |||||
| SII-H/T2DM | 96/1440 | Reference | NA | Reference | NA |
| SII-L/T2DM | 126/2516 | 0.74 (0.56–0.96) | 0.024 | 0.76 (0.58–1.00) | 0.047 |
| SII-H/Non-T2DM | 65/1687 | 0.57 (0.41–0.77) | <0.001 | 0.58 (0.42–0.81) | 0.001 |
| SII-L/Non-T2DM | 106/2959 | 0.52 (0.40–0.69) | <0.001 | 0.57 (0.43–0.76) | <0.001 |
Notes:*Model adjusted for age, male, hypertension, dyslipidemia, prior MI, prior PCI/CABG, hsCRP, creatinine, LM/three-vessel disease, CTO, number of stents, SYNTAX score, total length of stents and average diameter of stents. †P for trend for the risk of MACE: <0.001.
Abbreviations: MACE, major adverse cardiovascular events; SII, systematic immune-inflammation index; T2DM, type 2 diabetes mellitus; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; hsCRP, high-sensitivity C-reactive protein; SYNTAX, synergy between PCI with taxus and cardiac surgery; NA, not applicable; HR, hazard ratio; CI, confidence interval.